News | News By Subject | News by Disease News By Date | Search News

Attention Deficit Syndrome News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Shire Reports Results From Two Head-To-Head Studies Comparing Vyvanse® With Concerta® In ADHD Study     7/18/2014
FDA Warns Consumers About Fake Versions of Teva Pharmaceutical Industries Limited (TEVA)'s Adderall     5/30/2012
Targacept, Inc. (TRGT) Drug Fails at Phase II ADHD Trial     3/24/2011
Eli Lilly and Company (LLY) Wins Longer Halt Of Generic Strattera Sales     8/27/2010
Shire plc Non-Safety-Related Voluntary Recall of a Limited Portion of Daytrana(R) Patches Announced     12/3/2009
FDA Approves Additional Dosage Strengths of Shire Pharmaceuticals Group plc (SHPGY)'s ADHD Treatment VYVANSE(TM)     1/3/2008
Shire Pharmaceuticals Group plc (SHPGY) Release: Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD     11/30/2007
FDA Rejects Cortex Pharmaceuticals, Inc. (COR)'s Request for Study of Drug Candidate     10/11/2007
Shire Pharmaceuticals Group plc (SHPGY) Receives Approvable Letter From FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD     6/21/2007
Shire Pharmaceuticals Group plc (SHPGY) Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents     5/24/2007
FDA Issues Approvable Letter for Shire Pharmaceuticals Group plc (SHPGY)'s SPD465 for the Treatment of ADHD in Adults     5/21/2007
Shire Pharmaceuticals Group plc (SHPGY) (Jobs) and New River Pharmaceuticals Inc. (NRPH) Announce FDA Approval of The First and Only Stimulant Prodrug VYVANSE(TM) as a Novel Treatment for ADHD     2/26/2007

News from Around the Web
DEHP Plasticizer In Medical Devices Linked To ADD, Katholieke Universiteit Reveals     4/12/2016
Childhood ADHD Linked to Later Risk of Drug Abuse: Journal of the American Academy of Child & Adolescent Psychiatry     6/2/2011
Alzheimer's ... Or Something Else? - Kuakini Medical System Study     2/25/2011
One Million More U.S. Kids Are Diagnosed With Attention Deficit, Centers for Disease Control and Prevention (CDC) Reveals     11/11/2010
Effective ADHD Treatment Found For Children With Fragile X Syndrome     2/22/2008
19% of ADHD Patients Get Too Many Drugs     12/7/2007
Drugs for ADHD 'Not the Answer'     11/12/2007
Gov't to Study Heart Risks of ADHD Drugs     9/18/2007
Bupropion Doesn't Prevent Smoking in ADHD Patients     8/30/2007
Gene Predicts Better Outcome as Cortex Normalizes in Teens with ADHD     8/7/2007
Improvement Following ADHD Treatment Sustained in Most Children     7/23/2007
Massachusetts Institute of Technology (MIT) Neuroscientists Find Different Brain Regions Fuel Attention; Work Could Be Significant in Treatment of ADD     3/30/2007
Study Shows Near Tripling of Global ADHD Drug Use     3/7/2007
US FDA Tells ADHD Makers To Warn Patients Of Risks     2/21/2007
ADHD Treatment Safe And Effective For Preschoolers     10/31/2006

Press Releases
Alcobra (ADHD) Provides Update On Recent FDA Meeting And Path Forward For MDX Clinical Development Program     1/9/2017
Mylan (MYL) Launches Generic Dexedrine Capsules     8/1/2016
Kyowa Hakko Release: Groundbreaking Study In Journal Of Attention Disorders Finds That Daily Cognizin Citicoline Oral Supplement Improves Attention In Adolescent Males     8/11/2015
Shire Pharmaceuticals Group plc (SHPGY) Provides Regulatory Update On SHP 465, Investigational Compound For ADHD In Adults     10/9/2014
Shire Pharmaceuticals Group plc (SHPGY) Agrees To FDA Request To Conduct Clinical Trials Investigating The Potential Use of Vyvanse® (lisdexamfetamine dimesylate) In Preschool-Age Children With ADHD     6/12/2014
Florida International University Study Reveals Tie Between Mothers With ADHD And Children With ADHD Or Autism     6/12/2014
Shire plc Release:” New Phase 3 Data For Guanfacine Extended Release (GXR) To Be Presented At European Congress Of Psychiatry     2/27/2014
Suven Life Sciences Ltd's Alzheimer Drug Candidate SUVN-502 Successfully Completed All Chronic Toxicological (tox) Studies and Demonstrated Very High Margin of Safety (MOS)     5/18/2011
McNeil Pediatrics: New Data Analyses of CONCERTA(R) Efficacy on ADHD in the Classroom     5/26/2010
Shire plc: Study Evaluated Vyvanse(R) Capsules CII Efficacy and Safety in Adolescents with ADHD     5/26/2010
Shire plc Study Data Show INTUNIV(TM) (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents     5/21/2010
Shire plc to Present Scientific Data and Research Findings on ADHD Treatments at Two Upcoming National Scientific Psychiatry Meetings     5/19/2010
Shire plc: FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD     5/4/2010
Mylan Inc. (MYL) Begins Marketing First Generic Version of Desoxyn(R)     4/26/2010
GlaxoSmithKline Consumer Healthcare Release: Nicotine Replacement Therapy Is Safe, Effective and Can Help Reverse Mental Acuity Deficits in Smokers Who Are Quitting, Including Commercial and Private Pilots Commit 4 mg Lozenge Helps Reverse Symptoms Associated with Nicotine Withdrawal Including Difficulty Concentrating, Attention Deficit, Memory Deficit and Selective Attention Deficit     5/23/2008